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ABSTRACT  22 
Background. Immunological monitoring for CMV can be useful in transplant patients; however, 23 
few centers perform it on a routine basis.  24 
Objectives. In this study, CMV-specific cellular response was evaluated in a population of kidney 25 
transplant recipients and related to viral infection/reactivation and other demographic and clinical 26 
features.  27 
Study design. Three-hundred-twenty-eight patients were studied by EliSPOT assay: 201 28 
prospectively monitored in the first year posttransplantation, 127 with a single determination at >1 29 
year. Clinical features, including occurrence of CMV-DNAemia, CMV serostatus, anti-viral 30 
strategies and immunosuppressive protocols, were evaluated.  31 
Results. Overall, 66.5% of patients were CMV- responders at EliSPOT assay. No episode of 32 
infection occurred at follow-up (mean 24.5 months) in 73.4% responders versus 55.5% non-33 
responders (p <0.005); CMV-free period was significantly longer in responders (p<0.001). 34 
Although no significant difference of peak viral load was found, prevalence of CMV-DNAemia 35 
values >10
5
 copies/mL was significantly higher in non-responders versus responders (8.2% and 36 
2.3%, p<0.05). Non-responder status was significantly associated to CMV-seronegativity (p 37 
<0.0001), anti-viral prophylaxis use (p <0.0001), and immunosuppression induction with 38 
basiliximab (p <0.005). No significant association was found for other clinical features and 39 
immunosuppressive protocols.  40 
Conclusions. Immunological data for CMV could be used in the clinical evaluation and decision-41 
making process, in combination with virological monitoring, in kidney transplant recipients. 42 
. 43 
Keywords: cytomegalovirus; cellular immune response; EliSPOT assay; CMV-DNAemia; kidney 44 
transplantation. 45 
46 
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Background 47 
In transplant patients, Cytomegalovirus (CMV) may reactivate from latency due to 48 
immunosuppression or cause primary infection in seronegative recipients. In kidney transplantation 49 
(KT), CMV infection and disease have been reported in 8%-32% and 8%, respectively [1]; 50 
moreover, CMV has been associated to indirect effects, including rejection, chronic nephropathy, 51 
and other opportunistic infections [1-3]. As CMV-specific T-cell response has been associated to 52 
decreased rates of infection/disease [4-11], its evaluation  may be valuable in combination with 53 
viral monitoring, according to the Updated International Consensus Guidelines on the Management 54 
of Cytomegalovirus in Solid Organ Transplantation [12]. Assays for immunological evaluation 55 
include intracellular cytokine staining, MHC multimer staining, QuantiFERON-CMV, and 56 
EliSPOT. An ideal assay should evaluate CD4+ and CD8+ T-cell response, optimally by measuring 57 
interferon (IFN)-γ, and should be simple, rapid, cost-effective, and reproducible. At moment, no 58 
assay is standardized with the exception of the QuantiFERON-CMV that, however, only evaluates 59 
CD8+ responses. Other limitations include the need for a flow cytometer (intracellular cytokine 60 
staining, MHC multimer staining) and HLA restriction (MHC multimer staining). EliSPOT 61 
enumerates IFN-γ-secreting mononuclear cells (both CD4+ and CD8+, without differentiating) in 62 
response to stimulus with CMV peptides and seems to represent a reproducible tool for monitoring 63 
T-cell activity ex-vivo [12]. Current evidence suggests that viro-immunogical evaluation can predict 64 
the risk of CMV viremia and disease in the postprophylaxis and preemptive context [4-11]. At 65 
moment, very few Italian centres perform CMV-specific immunological evaluation and its 66 
implications in the clinical decision-making process are poorly defined. The Turin Renal Transplant 67 
Centre is the first in Italy for activity volume (>100 KT/year).  68 
 69 
Objectives 70 
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To evaluate CMV-specific cellular immune status in KT patients on a routine basis and investigate 71 
the association to viremia, demographic and clinical features.  72 
Study design 73 
Three-hundred-twenty-eight consecutive KT recipients (M/F, 218/110; mean age, 54.7±14.2 years; 74 
range, 28-75) were investigated in a mixed prospective-cross sectional study: 201 prospectively 75 
monitored in the first year posttransplantation and 127 at >1 year (up to eight). Main features of 76 
study population are summarized in Table 1. Informed written consent was obtained from all 77 
patients; the study was conducted in accordance with the ethical standards and Helsinki Declaration 78 
and approved by the Institutional Review Board. According to our centre’s practice, virological 79 
monitoring was performed by quantification of CMV-DNAemia on whole blood (using a 80 
commercially available real-time PCR assay [CMV-ELITe MGB® kit, ELITechGroup, Milan, 81 
Italy]) twice weekly in the first month, twice monthly up to 3 months, every three months up to 1 82 
year, and yearly thereafter. Further specimens were collected in the presence of CMV-DNAemia, 83 
usually within 7 days. Immunological evaluation was scheduled at 30, 60, 90, 180, and 360 days in 84 
the first year posttransplantation; and once at any time point at >1 year. No baseline immunological 85 
evaluation was made and no further specimens were collected in the presence of CMV-DNAemia. 86 
However, due to missing sending or specimen unsuitability (i.e. insufficient number of cells, invalid 87 
positive or negative control; see below for details), only 705 samples were available from the 201 88 
patients evaluated in the first year posttransplantation (mean, 3.5/patient), in addition to 127 89 
specimens from as many patients at >1 year, accounting for an overall number of 832 specimens. 90 
Data of CMV-DNAemia were available for all patients (median time of follow-up 24.5 months, 91 
range 24-42). Anti-CMV prophylaxis was administered for 3 months in high risk patients (i.e. 92 
donor/recipient seromatching, D+/R-, N=30)[13]. Pre-emptive treatment with ganciclovir or 93 
valganciclovir was administered in case of CMV-DNAemia >10
4
 copies/mL or based on clinical 94 
judgment.  95 
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EliSPOT was performed as described elsewhere [14]. Briefly, automated separation of T cells from 96 
fresh blood samples was performed with the RoboSepR instrument (StemCell Technologies, 97 
Vancouver, Canada) using the EasySep
TM
 Whole Blood T Cell Enrichment kit for immunomagnetic 98 
negative selection (StemCell Technologies), following the manufacturer’s instruction. This system 99 
isolates cells from HetaSepTM-treated (ratio 1:5; StemCell Technologies) whole blood by targeting 100 
unwanted cells for removal with Tetrameric Antibody Complexes recognizing CD14, CD16, CD19, 101 
CD20, CD33, CD36, CD41, CD56, CD66b, CD123, glicophorin A and dextran-coated magnetic 102 
particles; the labeled cells are separated using the EasySep
TM
 magnet, whereas desired cells are 103 
poured off into a new tube. According to manufacturer’s, this system allows for an enrichment in 104 
CD3+ fraction (approximately from 11% to >96%), with recovery of also dendritic cells and a 105 
minimal amount of other cells, such as macrophages and B lymphocytes, functioning as antigen 106 
presenting cells. No further method to assess specimen purity was used. Separated cells were 107 
resuspended in RPMI-1640 medium (supplemented with 1% L-glutammine and 10% fetal calf 108 
serum). An aliquot of 2x10
5
 CD3+ cells (100 μL/well from a 2x106/mL mix) was incubated for 20-109 
24 h on an anti-IFN-γ antibody-coated plate (EliSPOT Interferon-γ Basis Kit; Autoimmun 110 
Diagnostika, Strassberg, Germany) with CMV-specific peptide mix (CMV-Spot ELSP5530, 111 
including pp65 and IE-1; Autoimmun Diagnostika), medium alone (negative control) or 112 
phytohemagglutinin (positive control). IFN-γ production was visualized by an enzyme-labeled 113 
detection antibody, with each spot representing a single cell secreting IFN-γ. Results were analyzed 114 
using a computer-assisted system (AID EliSPOT Reader System, Autoimmun Diagnostika). 115 
Background was subtracted for all the results (sample minus negative control). Results were 116 
expressed as spot forming units (SFU)/2x10
5
 CD3+ cells. Specific immune response was evaluated 117 
as previously described [15]: invalid assay >5 SFU for the negative control and <20 for the positive 118 
control; absent/weak response <20, strong response ≥20 (accordingly, non-responders and 119 
responders patients).  120 
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Demographic and clinical variables were evaluated by univariate analysis and subsequently 121 
included in a multivariate logistic regression analysis. The t test was used for comparisons of 122 
quantitative variables between groups. Time to development of CMV reactivation was evaluated by 123 
Kaplan-Meier curve analysis. Evaluation of an intersection point with high specificity and 124 
sensitivity to differentiate patients with and without occurrence of CMV viremia in the subsequent 3 125 
months on the basis of SFU values was made by ROC curve analysis. A commercially available 126 
software was used (IBM SPSS Statistics version 21). A p value <0.05 was considered statistically 127 
significant. 128 
 129 
Results 130 
Overall, 218/328 (66.5%) patients were CMV-responders (median SFU/2x10
5
 CD3+ cells 131; 131 
range, 20-500); in particular, 125/201 (62.2%) individuals evaluated in the first year 132 
posttransplantation (in this subgroup of patients, immunological status was defined considering the 133 
whole period of study for each individual), with restoration of immune response within 6 months, 134 
and 86/127 (67.7%) at >1 year. In Figure 1, rate of responders and median SFU/2x10
5
 CD3+ cells 135 
at different time points are reported. At least one episode of viremia occurred in 107/328 (32.6%) 136 
patients at follow-up: 58/218 (26.6%) responders versus 49/110 (44.5%) non-responders (p=0.002); 137 
with repeated episodes of infection occurring in 13/218 (6.0%) versus 18/110 (16.4%; p=0.005), 138 
respectively (Figure 2a). Viral load (peak level) tended to be higher in non-responders, although  139 
difference was not significant (mean±standard deviation: 1.1x105±3.4x105 and 3.8x105±8.4x105 140 
copies/mL in responders and non-responders, respectively; p >0.3)(Figure 2b). However, a 141 
significantly higher prevalence of DNAemia values >10
5
 copies/mL was found in non-responders 142 
versus responders (9/110, 8.2% versus 5/218, 2.3%, respectively, p<0.05)(Figure 2c). Kaplan-Meier 143 
analysis evidenced that CMV-free cumulative incidence was significantly higher in responders 144 
versus non-responders (p<0.001; Figure 3). No case of CMV disease occurred at follow-up. 145 
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Subsequently, relation between demographic and clinical features and CMV-specific immune status 146 
and viremia was evaluated (Table 2). At univariate analysis, non-responder status was significantly 147 
associated to male gender (p<0.05), seronegative recipient status (R-) at transplantation (p<0.0001), 148 
antiviral prophylaxis (p<0.0001), and immunosuppression induction with basiliximab (p<0.005); 149 
whereas no association was found for other features, including age, time from transplantation, 150 
immunosuppressive induction with anti-thymocyte globuline and immunosuppressive protocols 151 
including calcineurin-inhibitors and mTOR-inhibitors.  152 
In particular, 28/39 (71.8%) R- patients were non-responders irrespective of donor serostatus, 153 
whereas the remaining R- individuals developed a CMV-specific cellular immune response in the 154 
first year posttransplantation following primary infection. Among D-/R- patients, one subject 155 
developed a primary infection at 1 month (viral load, 2,071,000 CMV-DNA copies/mL). As 156 
expected, EliSPOT evidenced a non-responder status in the first months posttransplantation, with 157 
development of CMV-specific response at 6 months (20 SFU//2x10
5
 CD3+ cells). For the analysis, 158 
this patient was included among the responders, however this level of response was only partially 159 
maintained (subsequent EliSPOT values between 12 and 20). On the other hand, 207/289 (71.6%) 160 
R+ patients displayed a responder status (p<0.001). 161 
High risk patients (D+/R-) on antiviral prophylaxis usually exhibited a non-responder status, as 162 
expected; while pre-emptive treatment was associated with recovery and presence of CMV-specific 163 
cellular immune response (p<0.001). 164 
As regards immunosuppression, only induction with basiliximab was significantly associated to a 165 
non-responder status. It is to note that anti-thymocyte globulin was used only in six patients, five of 166 
which reconstituted CMV-specific cellular immune response within three months.  167 
Multivariate analysis of demographic and clinical features in relation to CMV non-responder status, 168 
evidenced a significant association for R- serostatus (p<0.0001; hazard ratio [HR] 13.02, 95% 169 
confidence interval [CI] 5.21-32.5) and male gender (p<0.005; HR 2.40, 95% CI 1.36-4.24).  170 
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Among demographic and clinical features evaluated at univariate analysis for the occurrence of 171 
CMV viremia (Table 2), a significance was found only for age >50 years and induction with 172 
basiliximab. No factor resulted significantly associated at multivariate analysis. 173 
Figure 4 illustrates ROC curve analysis for SFU/2x10
5
 CD3+ cells values in terms of occurrence of 174 
CMV-DNAemia in the subsequent 3 months.  175 
 176 
Discussion 177 
In the present study, CMV immunogical data were routinely investigated in KT recipients by 178 
EliSPOT, in contrast to previous studies performed on selected or voluntarily recruited patients and 179 
more often by QuantiFERON-CMV assay. The optimization of the method with automated 180 
separation of total CD3+ cells could improve specificity of this application, as EliSPOT usually 181 
enumerates IFN-γ secreting mononuclear cells without distinguishing between NK and T cells.  182 
Although the lack of baseline immunological data should be considered, most of the patients 183 
evidenced recovery of CMV-specific T-cell response within the first months posttransplantation:  184 
53.1% (median, >70 SFU/2x10
5
 CD3+ cells) at 3 months up to approximately 65% (median, >100) 185 
at 6 months. Response was persistent throughout the follow-up with no subsequent relevant 186 
increase in the total rate of responders and level of response. At follow-up, recovery of response 187 
was significantly associated to a lower incidence of viremia (26.6% versus 44.5% in responders and 188 
non-responders, respectively). In responders, episodes of infection were characterized by low level 189 
CMV-DNAemia (< or slightly >2x10
3
 copies/mL, limit of detection of the real-time PCR assay) 190 
and short duration (negative on subsequent evaluation, in the absence of antiviral administration). In 191 
non-responders, occurrence of CMV-DNAemia was significantly higher, in particular repeated 192 
episodes of infection; the higher occurrence of values >10
5
 copies/mL suggests a potential impact 193 
on uncontrolled replication. It is to note that antiviral administration was based on clinical judgment 194 
and/or CMV-DNAemia values >10
4
 copies/mL. It has been hypothesized that a certain level of viral 195 
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replication is required to stimulate an adequate immune response: CMV-DNAemia from 7000 196 
copies/mL in R- patients when prophylaxis was discontinued in a previous study [7]. On the other 197 
hand, the prompt administration of antivirals could interfere with immunological boost by reducing 198 
viral exposure. This could explain the significantly higher frequency of repeated episodes of 199 
reactivation in non-responders, as no sufficient exposure was accomplished by administrating the 200 
antiviral agent for low viral loads.  201 
Considering serological matching and antiviral strategy, prophylaxis-treated D+/R- patients did not 202 
usually mount an adequate response (73.3% non-responders up to 1 year posttransplantation), as 203 
previously reported [7]. Despite of the high effectiveness of prophylaxis, primary infection may 204 
occur, thus probably determining the priming of CMV-specific cellular response. This is well 205 
recognized in KT (38% of 13 seronegative patients in the study by Abate and coll. [7]), as well as in 206 
lung transplantation [16,17]. Priming of response can also occur in D-/R- patients following a 207 
community-acquired infection. Seronegative status at transplantation and prophylaxis were among 208 
the few factors significantly associated to the lack of an adequate response at univariate analysis; 209 
association to seronegativity was highly significant also at multivariate analysis.  210 
Considering immunosuppression, induction with basiliximab was significantly associated to non-211 
responder status and viremia in our study, in contrast with previously reported data. Basiliximab is 212 
an IL-2 receptor antagonist that intervenes in a critical pathway involved in allograft rejection, thus 213 
impairing the immune response to antigenic challenges. Nevertheless, previous studies have 214 
reported similar incidence of CMV infection in basiliximab-treated patients and controls (17.3% 215 
versus 14.5%) [18]. It could be hypothesized that other factors such as serostatus, antiviral strategy 216 
or prophylaxis, and immunosuppressive protocols (triple immunosuppression including calcineurin-217 
inhibitors) play a role [19]. Protocols without mTOR inhibitors appear to delay CMV-specific 218 
immune response and contribute to the onset of infection/disease in KT patients [20]; this has been 219 
reported for lymphocyte-depleting agents (i.e. antithymocyte globulin) and calcineurin-inhibitor-220 
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based regimens. In the present study, antithymocyte globulin was used only in six patients, 221 
therefore no conclusion can be drawn; whereas the association between non-responder status and 222 
the commonly used protocols including a calcineurin-inhibitor was only marginally significant. 223 
Previous studies have evidenced a reduced incidence of CMV events for everolimus-treated 224 
patients, in particular in the absence of prophylaxis [21-25]. Among the proposed mechanisms for 225 
anti-CMV activity of mTOR inhibitors, an action on antiviral CD8+ memory T-cell generation has 226 
been hypothesized [21].  227 
An interesting finding was the higher frequency of non-responder status in men; it could be 228 
hypothesized that sex might have an effect on patterns of CMV-response per se or that this is due to 229 
differences in clinical features and management strategies (e.g., seronegativity more frequent in 230 
males, 13.8% versus 6.4%), as previously reported for some CMV indirect effects [26].  231 
In conclusion, viro-immunological routine monitoring of CMV evidenced that restoration of 232 
specific T-cell response is frequently and stably achieved within few months posttransplantation 233 
and is associated to a favorable outcome in terms of reactivation risk. Levels of response of 20 234 
SFU/2x10
5
 CD3+ cells could be regarded as useful in terms of sensitivity and specificity for 235 
evaluating the risk of viral reactivation. A subgroup of KT can display a persistently non-responder 236 
status that could be due to other host-related determinants.  237 
Based on this and considering the need for optimizing economic resources, the Turin Renal 238 
Transplant Centre has proposed the subsequent protocol for CMV immunological monitoring in 239 
KT: first evaluation at one month posttransplantation, in responders no further controls unless 240 
therapy modifications, rejection or CMV infection occur; in responders with the above mentioned 241 
conditions or non-responders, immunological evaluation in parallel to CMV-DNA up to 6 months 242 
or up to the development of a responder status with a re-control at 12 months. A single study using 243 
the QuantiFERON-CMV assay has also proposed the evaluation of pretransplant CMV responder 244 
status to stratify the risk of viral reactivation posttransplantation [27]. The usefulness of EliSPOT 245 
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assay in this context has not been yet investigated and specific investigations are needed. Further 246 
studies evaluating prophylaxis and pre-emptive treatment (in particular, the potential for defining 247 
cut-off levels for starting pre-emptive treatment also on the basis of immunological status) are 248 
needed, taking into consideration that a definitive evidence that immunological monitoring may 249 
guide successful clinical intervention or add value to virological monitoring is still lacking. 250 
Similarly, also the impact of immunosuppressive protocols, and other patient’s and viral 251 
determinants in relation to CMV-specific immunological status should be further investigated in 252 
order to optimize the management of KT recipients.  253 
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 332 
Figure 1. Rate of responders at different time points posttransplantation. For each time point, 333 
the median number of spot forming unit (SFU)/10^5 CD3+ cells is reported. Empty spaces in the 334 
graph are for time intervals. Number of patients tested as the individual time points: 169 at 30 days, 335 
124 at 60, 108 at 90, 156 at 180, 148 at 360 (considering an overall number of 201 patients 336 
prospectively studied in the first year posttransplantation) and 127 patients at >360. 337 
 338 
Figure 2. Occurrence of CMV-DNAemia in relation to CMV-specific cellular immune 339 
response. Percentages of patients with no episode, single episode or repeated episodes of CMV 340 
infection at follow up (mean 24.5 months, range 24-42) in responder and non-responder groups 341 
(Figure 2a). Mean viral load in the two groups; values are expressed as log10 copies/ml whole blood 342 
(peak level in each patient)(Figure 2b). Percentages of patients with CMV-DNAemia levels higher 343 
or lower than 10
5
 copies/mL whole blood in the two groups (peak level in each patient)(Figure 2c). 344 
 345 
Figure 3. Kaplan-Meier curve showing the time to occurrence of CMV viremia in responders 346 
(continuous line) versus non-responders (dotted line) who presented at least one episode of 347 
infection within 24 months posttransplantation.  348 
 349 
Figure 4. Evaluation of operating characteristics for spot forming units (SFU/2 x 10
5
 CD3+ 350 
cells) values in terms of occurrence of CMV-DNA in the subsequent 3 months by ROC curve 351 
analysis. 5 SFU/2x105 CD3+ cells: 51.4% sensitivity (95% confidence interval [CI] 41.5-61.3), 71.0% specificity 352 
(95% CI 66.6-75.1); 20 SFU/2x10
5
 CD3+ cells, 71.4% sensitivity (95% CI 61.8-79.8), 60.0% specificity (95% CI 55.3-353 
64.5); 100 SFU/2x10
5
 CD3+ cells, 89.5% sensitivity (95% CI 82.0-94.5), 38.5% specificity (95% 34.1-43.1). 354 
 355 
356 
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Table 1. Main features of study population. 357 
 Total  
N= 328 
Age, mean ± SD (range), years 54.7 ± 14.2 (28-75) 
Gender  
  Male 
  Female    
 
218 (66.5%) 
110  (33.5%) 
CMV serological matching  
  D+/R+ 
  D-/R+ 
  D+/R- 
  D-/R-   
 
259 (79.0%) 
30 (9.1%) 
30 (9.1%) 
9 (2.8%) 
Time from transplantation 
  < 1 year  
  > 1 year (up to 8) 
 
201 (61.3%) 
127 (38.7%) 
Immunosuppression induction 
  ATG 
  Basiliximab 
 
6 (1.8%) 
238 (72.6%) 
Immunosuppressive protocol 
Including CNI 
  Tac, MMF, steroid 
  Tac, steroid 
  CyA, MMF, steroid 
  CyA, steroid 
  Others  
Including mTOR inhibitors (everolimus, sirolimus) 
 
313 (95.4%) 
177 (54.0%) 
81 (24.7%) 
17 (5.2%) 
8 (2.4%) 
30 (9.1%) 
28 (8.5%) 
Antiviral strategy 
  Prophylaxis (D+/R-) 
  Pre-emptive therapy (D+/R+, D-/R+) 
  None (D-/R-) 
 
30 (9.1%) 
289 (88.1%) 
9 (2.8%) 
 358 
 359 
N, number; SD, standard deviation; D, donor; R, recipient; ATG, antithymocyte globulin; CNI, 360 
calcineurin inhibitors; Tac, tacrolimus; MMF, mycophenolate mofetil; CyA, cyclosporine A; 361 
mTOR, mammalian target of rapamycin. 362 
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Table 2. Relation between demographic and clinical features of study population and CMV-specific cellular immune response status and 363 
viremia occurrence.  364 
 365 
Feature N Non-
responders 
N (%) 
OR (95% CI) p CMV-viremia 
N (%) 
OR (95% CI) p  
Sex 
  M 
  F 
 
218 
110 
 
82 (37.6) 
28 (25.4) 
 
0.5663  
(0.3404-0.9422) 
 
0.0286 
 
71 (32.6) 
36 (32.7) 
 
0.9928 
(0.6090-1.6186) 
 
0.9769 
Age ≥ 50 years 
  Yes 
  No 
 
221 
107 
 
78 (35.3) 
32 (29.9) 
 
0.7822  
(0.4757-1.2863) 
 
0.3331 
 
82 (37.1) 
25 (23.4) 
 
1.9350 
(1.1453-3.2690) 
 
0.0136 
Recipient CMV serostatus  
  R+ 
  R- 
 
289 
39 
 
82 (28.4) 
28 (71.8) 
 
6.4257  
(3.0570-13.5065) 
 
             <0.0001 
 
97 (33.6) 
10 (25.6) 
 
1.4651  
(0.6858-3.1300) 
 
0.3241 
Anti-viral prophylaxis 
  Yes (D+/R-) 
  No (D+/R+, D-/R+,  D-/R-) 
 
30 
298 
 
22 (73.3) 
88 (29.5) 
 
0.1524  
(0.0654-0.3553) 
 
            <0.0001 
 
8 (26.7) 
99 (33.2) 
 
0.7309 
 (0.3142-
1.7005) 
 
0.4669 
Time from transplantation 
  < 1 year   
   > 1 year  
 
201 
127 
 
69 (34.3) 
41 (32.3) 
 
0.9120  
(0.5687-1.4627) 
 
0.7024 
 
75 (37.3) 
32 (25.2) 
 
0.8306  
(0.5044-1.3678) 
 
0.4657 
Immunosuppression induction with 
basiliximab 
  Yes 
  No   
 
 
235 
93 
 
 
90 (38.3) 
20 (21.5) 
 
 
0.4414  
(0.2521-0.7729) 
 
 
0.0042 
 
 
101 (43.0) 
6 (6.5) 
 
 
10.9291  
(4.5940-
26.0002) 
 
             
 
            < 0.0001 
Immunosuppression induction with 
anti-thymocyte globuline 
  Yes 
  No 
 
 
6 
322 
 
 
1 (16.7) 
109 (33.8) 
 
 
2.5587  
(0.2952-22.1744) 
 
 
0.3938 
 
 
2 (33.3) 
105 (32.6) 
 
 
1.0333  
(0.1863-5.7323) 
 
 
0.9701 
Immunosuppressive protocol including 
calcineurin-inhibitors (cyclosporine A, 
tacrolimus) 
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  Yes 
  No 
313 
15 
110 (35.1) 
0 (0) 
0.0594  
(0.0035-1.0024) 
0.0502 105 (33.5) 
2 (13.3) 
3.2813  
(0.7270-
14.8104) 
0.1223 
Immunosuppressive protocol including 
mTOR-inhibitors (everolimus, 
sirolimus) 
  Yes 
  No 
 
 
 
28 
300  
 
 
 
13 (46.4) 
97 (32.2) 
 
 
 
0.05513  
(0.2525-1.2041) 
 
 
 
0.1352 
 
 
 
9 (32.1) 
98 (32.7) 
 
 
 
0.9764  
(0.4262-2.2369) 
 
 
 
0.9549 
Total 328 110 (33.5)   107 (32.6)   
 366 
 367 
D, donor; R, recipient; OR, odds ratio; CI, confidence interval.368 
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2c 387 
 388 
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3 390 
 391 
392 
24 
 
4 393 
5
20
100
Area under the ROC curve (AUC) 0.685
Standard error 0.0261
95% CI 0.6466-0.724
p = 0.0001
 394 
 395 
